Acrux Receipt of R&D Tax Incentive Rebate – Overseas Finding Application for Acrux Pharma Pty Ltd

Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]

Congenica named in UK’s Digital Health Playbook – ‘First 100’ Companies

Link to Full Article Cambridge, United Kingdom – 27 May 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, has been featured in the UK’s Digital Health Playbook – ‘First 100’. An initiative by the Department of International Trade to highlight the nation’s most innovative and impactful digital health companies.    The First 100 list features UK businesses with a proven track record of benefiting […]

Destiny Pharma Notice to Register for 2021 AGM

Link to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]

Adherium announces appointment of Mr. Rick Legleiter as Chief Executive Officer and welcomes Mr. George Baran to the Board

Link to Full Article Melbourne, Australia – 13 May 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, announces the appointment of Rick Legleiter as Chief Executive Officer of Adherium. The Board also announces the appointment of George Baran as a Non-Executive Director. Mike Motion, Adherium’s current CEO and […]

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

Link to Full Article Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided […]

Saluda Medical Announces Publication of 24-Month Spinal Cord Stimulation Results with the Evoke® System

Link to Full Article Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high […]

The Electrospinning Company – £4.5M Investment Led by Confluent Medical

Link to Full Article Proceeds to be used to expand electrospinning capabilities & capacity, driving company growth    Harwell, UK, May 4 2021 – The Electrospinning Company (Electrospinning), a leader in the development and manufacture of nanofibrous biomaterials for use in tissue regenerative devices, has completed a £4.5m ($6.3m) fundraising round, led by US materials science company Confluent Medical Technologies Inc. (Confluent) […]

Destiny Pharma – Posting of Annual Report and Notice of AGM

Link to Full Article Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 4 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company’s website at www.destinypharma.com […]

Adherium Quarterly Cash Flow Report to 31 March 2021

Link to Full Article All figures are stated in Australian dollars and are unaudited.  Adherium Limited (ASX: ADR), a leader in digital inhaled device adherence, remote monitoring, and data management solutions, presents its Appendix 4C cash flow report for the quarter ended 31 March 2021. During the quarter Adherium received $18 million of investment commitments […]

GEN INCODE ANNOUNCES MAJOR UK COLLABORATION WITH ROYAL BROMPTON AND HAREFIELD HOSPITALS

Link to Full Article GEN inCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today a collaboration with Royal Brompton and Harefield hospitals (“RB&H”), recently merged with Guy’s and St Thomas’ NHS Foundation Trust (“GSTT”), to provide globally leading cardiovascular disease clinical genetic testing and reporting. GEN inCode specializes […]